Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeuticsnews2025-02-28T15:13:45+00:00February 28th, 2025|Endpoints News|
Hansoh ends collaboration with Silence; Vir hunts for HBV drug partnernews2025-02-27T15:09:04+00:00February 27th, 2025|Endpoints News|
Harbour BioMed inks deal up to $395M; ORIC refines plans for two drugsnews2025-02-26T15:29:08+00:00February 26th, 2025|Endpoints News|
Repare to lay off 75% of staff; Castle Creek inks $75M royalty dealnews2025-02-25T15:39:56+00:00February 25th, 2025|Endpoints News|
FDA won’t allow Invivyd’s Pemgarda to treat Covid; Antibiotic biotech launchesnews2025-02-24T15:37:15+00:00February 24th, 2025|Endpoints News|
More biotechs announce share buybacks; Cosette to buy Mayne Pharmanews2025-02-21T15:30:02+00:00February 21st, 2025|Endpoints News|
Illumina to lay off about 100 people; Incyte’s new AI partnershipnews2025-02-20T15:17:34+00:00February 20th, 2025|Endpoints News|
Another Chinese biotech files to go public in Hong Kong; A new ROR1 ADC dealnews2025-02-19T15:07:12+00:00February 19th, 2025|Endpoints News|
Septerna ends Phase 1 trial for hypoparathyroidism drug; Sanofi’s Merilog is approvednews2025-02-18T15:46:39+00:00February 18th, 2025|Endpoints News|
Otsuka makes pipeline changes; Oculis reveals $100M offeringnews2025-02-14T15:55:31+00:00February 14th, 2025|Endpoints News|
